Scholarlink

<p>Hypertriglyceridemia can increase the risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). Patients with familial chylomicronemia syndrome are at an even higher risk of developing pancreatitis due to elevated triglycerides. A pathway involving small interfering RNA that selectively inhibits apolipoprotein C-III (APOC3) messenger RNA through RNA interference is currently being studied to reduce levels of apoC-III and thus, triglycerides. This review presents and discusses the current pharmacokinetic, pharmacodynamics, and clinical and scientific evidence pertaining to plozasiran, a small interfering RNA medicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Pharmacology of Plozasiran

  • 期刊论文

  • 发表日期：

    2026年6月24日

查看全文
  • Jessica Huston,
  • Dontia Orey,
  • Kelli Corona,
  • Andrew Ashchi,
  • Andrea Ashchi Lachapelle,
  • Elias Deeb,
  • Alexander Deeb,
  • Rambod Rouhbakhsh,
  • Jason Berner,
  • David Sutton,
  • Wasim Deeb,
  • Majdi Ashchi,
  • Amir Azarbal,
  • Rebecca F. Goldfaden

摘要

Hypertriglyceridemia can increase the risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). Patients with familial chylomicronemia syndrome are at an even higher risk of developing pancreatitis due to elevated triglycerides. A pathway involving small interfering RNA that selectively inhibits apolipoprotein C-III (APOC3) messenger RNA through RNA interference is currently being studied to reduce levels of apoC-III and thus, triglycerides. This review presents and discusses the current pharmacokinetic, pharmacodynamics, and clinical and scientific evidence pertaining to plozasiran, a small interfering RNA medicine.